Align Technology, Inc. ALGN is set to report third-quarter 2019 results on Oct 23, after the closing bell.
In the last reported quarter, the company delivered a positive earnings surprise of 21.2%. It has a four-quarter average positive earnings surprise of 9%.
Let’s take a look at how things are shaping up prior to this announcement.
Align Technology is expected to have gained from continued adoption of Invisalign system in the third quarter of 2019.
Invisalign portfolio expansion, anticipated revenue growth at the Clear Aligner segment on sustained Invisalign case volume growth across customer channels and geographies, and estimated growth in the teen patient segment are likely to aid the company’s results. We believe Invisalign First, Invisalign Lite, Invisalign Go and treatment with Mandibular Advancement have seen continued strength in the third quarter as well.
For the Americas, the company expects third-quarter Invisalign volumes to show sequential increase on growth in orthodontist and GP channels as well as continued uptick in the number of teenage patient cases.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote
For International markets, management expects third-quarter volumes to reflect sequential growth, mirroring seasonally stronger periods for the EMEA and APAC regions. For the to-be-reported quarter, the company anticipates strong Invisalign volume growth, particularly in China, Japan, Hong Kong and Taiwan. In Latin America, Align Technology’s continued investments in the Clear Aligner segment should get reflected in the company’s Invisalign volume growth in this geography.
Scanner & Service Business to Drive Q3
Align Technology has been generating solid revenues from the Scanner and Service business over the past few quarters. The company has been witnessing increased adoption of iTero scanners for Invisalign case submissions, especially in North America and the Asia-Pacific region. We expect this trend to get reflected in third-quarter results.
Continued adoption of the iTero Element 5D imaging system in EMEA, APAC and Canada is expected to have contributed to the company’s top line.
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for revenues is pegged at $592.5 million, indicating an improvement of 17.3% from the year-ago figure. The same for earnings per share is pinned at $1.14, suggesting a decline of 8.1%.
For the third quarter of 2019, the company projects revenues of $585-600 million (indicating 16-19% growth from a year ago). Operating margin for the quarter is estimated in the band of 19.8-20.5%. Further, continuation of the company’s operational expansion efforts might have resulted in third-quarter capital expenditure of $50-$55 million.
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.
Earnings ESP: Align Technology has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Align Technology carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season.
Akcea Therapeutics AKCA has an Earnings ESP of +18.18% and a Zacks Rank of 2.
Vertex Pharmaceuticals VRTX has an Earnings ESP of +2.28% and a Zacks Rank #1.
DENTSPLY SIRONA XRAY has an Earnings ESP of +5.05% and a Zacks Rank of 3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research